{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:12:50Z","timestamp":1783638770889,"version":"3.55.0"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001475","name":"Nanyang Technological University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001475","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine & Growth Factor Reviews"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cytogfr.2026.06.002","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:20:45Z","timestamp":1781652045000},"page":"70-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The role of osteoprotegerin in colorectal cancer: Molecular interactions, mechanistic insights, and therapeutic implications"],"prefix":"10.1016","volume":"90","author":[{"given":"Chester Yan Jie","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zipan","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3877-1914","authenticated-orcid":false,"given":"Linda L.D.","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cytogfr.2026.06.002_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA a cancer journal clinicians"},{"issue":"2","key":"10.1016\/j.cytogfr.2026.06.002_bib2","article-title":"Colorectal cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.cytogfr.2026.06.002_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2025.100727","article-title":"Bone metastasis in colorectal cancer: pathophysiology, prognostic factors, survival outcomes, and treatment strategies - a comprehensive review","volume":"55","author":"Hatoum","year":"2025","journal-title":"J. Bone Oncol."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.06.002_bib4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41698-023-00353-4","article-title":"Survival improvement for patients with metastatic colorectal cancer over twenty years","volume":"7","author":"Zeineddine","year":"2023","journal-title":"npj Precis. Oncol."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.06.002_bib5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41420-022-01042-0","article-title":"The roles of osteoprotegerin in cancer, far beyond a bone player","volume":"8","author":"Wang","year":"2022","journal-title":"Cell. Death Discov."},{"key":"10.1016\/j.cytogfr.2026.06.002_bib6","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3389\/fimmu.2014.00511","article-title":"Biology of the RANKL\u2013RANK\u2013OPG system in immunity, bone, and beyond","volume":"5","author":"Walsh","year":"2014","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.cytogfr.2026.06.002_bib7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.cytogfr.2026.06.002_bib8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1042\/CS20050175","article-title":"Role of osteoprotegerin (OPG) in cancer","volume":"110","author":"Holen","year":"2006","journal-title":"Clin. Sci."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.06.002_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10585-019-09997-8","article-title":"Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond","volume":"37","author":"Deligiorgi","year":"2020","journal-title":"Clin. & Exp. Metastas-.-."},{"issue":"3","key":"10.1016\/j.cytogfr.2026.06.002_bib10","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"De Visser","year":"2023","journal-title":"Cancer Cell."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.06.002_bib11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1006\/bbrc.1997.6603","article-title":"Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis","volume":"234","author":"Tsuda","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.cytogfr.2026.06.002_bib12","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.33263\/BRIAC102.193200","article-title":"Osteoprotegerin (OPG) pathways in bone diseases and its application in therapeutic perspectives","volume":"10","author":"Jayash","year":"2020","journal-title":"Biointerface Res. Appl. Chem."},{"issue":"9","key":"10.1016\/j.cytogfr.2026.06.002_bib13","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/jbmr.206","article-title":"A new role for OPG: putting RANKL in its place","volume":"25","author":"Ostrowski","year":"2010","journal-title":"J. Bone Mineral. Res."},{"issue":"45","key":"10.1016\/j.cytogfr.2026.06.002_bib14","doi-asserted-by":"crossref","first-page":"17523","DOI":"10.1074\/jbc.RA118.004489","article-title":"Dimerization interface of osteoprotegerin revealed by hydrogen\u2013deuterium exchange mass spectrometry","volume":"293","author":"Xiao","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.cytogfr.2026.06.002_bib15","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00018-008-8536-x","article-title":"Role of full-length osteoprotegerin in tumor cell biology","volume":"66","author":"Zauli","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"issue":"46","key":"10.1016\/j.cytogfr.2026.06.002_bib16","doi-asserted-by":"crossref","first-page":"24160","DOI":"10.1074\/jbc.M116.751974","article-title":"Heparan sulfate regulates the structure and function of osteoprotegerin in osteoclastogenesis","volume":"291","author":"Li","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.06.002_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00774-020-01191-1","article-title":"RANKL as the master regulator of osteoclast differentiation","volume":"39","author":"Takayanagi","year":"2021","journal-title":"J. Bone Mineral. Metab."},{"issue":"7","key":"10.1016\/j.cytogfr.2026.06.002_bib18","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.biocel.2010.03.018","article-title":"Colon carcinogenesis: learning from NF-kappaB and AP-1","volume":"42","author":"Vaiopoulos","year":"2010","journal-title":"Int. J. Biochem. Cell. Biol."},{"issue":"9","key":"10.1016\/j.cytogfr.2026.06.002_bib19","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00109-013-1045-x","article-title":"NF-\u03baB in colorectal cancer","volume":"91","author":"Vaiopoulos","year":"2013","journal-title":"J. Mol. Med."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.06.002_bib20","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar2165","article-title":"Biology of RANK, RANKL, and osteoprotegerin","volume":"9","author":"Boyce","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.cytogfr.2026.06.002_bib21","series-title":"TNF Receptor Associated Factors (TRAFs)","first-page":"152","article-title":"TRAFs in RANK Signaling","author":"Darnay","year":"2007"},{"issue":"11","key":"10.1016\/j.cytogfr.2026.06.002_bib22","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/bies.10352","article-title":"TRAF6, a molecular bridge spanning adaptive immunity, innate immunity and osteoimmunology","volume":"25","author":"Wu","year":"2003","journal-title":"Bioessays"},{"issue":"5","key":"10.1016\/j.cytogfr.2026.06.002_bib23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/cmi.2009.43","article-title":"NF-\u03baB signaling pathway, inflammation and colorectal cancer","volume":"6","author":"Wang","year":"2009","journal-title":"Cell. Mol. Immunol."},{"issue":"23","key":"10.1016\/j.cytogfr.2026.06.002_bib24","doi-asserted-by":"crossref","first-page":"14363","DOI":"10.1074\/jbc.273.23.14363","article-title":"Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL","volume":"273","author":"Emery","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.cytogfr.2026.06.002_bib25","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ceb.2010.08.001","article-title":"Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation","volume":"22","author":"Yang","year":"2010","journal-title":"Curr. Opin. Cell. Biol."},{"issue":"2","key":"10.1016\/j.cytogfr.2026.06.002_bib26","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a041053","article-title":"The death receptor pathway of apoptosis","volume":"14","author":"Green","year":"2022","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"15","key":"10.1016\/j.cytogfr.2026.06.002_bib27","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1158\/1078-0432.CCR-07-5019","article-title":"OPG is regulated by \u03b2-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer","volume":"14","author":"De Toni","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cytogfr.2026.06.002_bib28","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.3389\/fonc.2019.01248","article-title":"Multiple targets of the canonical WNT\/\u03b2-catenin signaling in cancers","volume":"9","author":"Lecarpentier","year":"2019","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.06.002_bib29","doi-asserted-by":"crossref","first-page":"a007898","DOI":"10.1101\/cshperspect.a007898","article-title":"The \u03b2-catenin destruction complex","volume":"5","author":"Stamos","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"4","key":"10.1016\/j.cytogfr.2026.06.002_bib30","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/jbmr.3351","article-title":"Osteoprotection through the deletion of the transcription factor Ror\u03b2 in mice","volume":"33","author":"Farr","year":"2018","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.cytogfr.2026.06.002_bib31","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/carcin\/bgt484","article-title":"Regulation of TRAIL receptor expression by \u03b2-catenin in colorectal tumours","volume":"35","author":"Jalving","year":"2014","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.cytogfr.2026.06.002_bib32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bone.2014.10.016","article-title":"STAT-6 mediates TRAIL induced RANK ligand expression in stromal\/preosteoblast cells","volume":"71","author":"Sundaram","year":"2015","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.06.002_bib33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4161\/epi.7.1.18753","article-title":"Role of DNA methylation in the regulation of the RANKL-OPG system in human bone","volume":"7","author":"Delgado-Calle","year":"2012","journal-title":"Epigenetics"},{"issue":"12","key":"10.1016\/j.cytogfr.2026.06.002_bib34","doi-asserted-by":"crossref","first-page":"15187","DOI":"10.18632\/oncotarget.7885","article-title":"Down-regulation of osteoprotegerin expression as a novel biomarker for colorectal carcinoma","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.cytogfr.2026.06.002_bib35","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.21873\/anticanres.13353","article-title":"Promoter methylation down-regulates osteoprotegerin expression in ovarian carcinoma","volume":"39","author":"Kim","year":"2019","journal-title":"Anticancer. Res."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.06.002_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/cells12010138","article-title":"The cytokine network in colorectal cancer: implications for new treatment strategies","volume":"12","author":"Braum\u00fcller","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.cytogfr.2026.06.002_bib37","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3389\/fonc.2016.00096","article-title":"Cytokine-induced modulation of colorectal cancer","volume":"6","author":"Mager","year":"2016","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.cytogfr.2026.06.002_bib38","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1359\/jbmr.070508","article-title":"Further insights in the mechanisms of Interleukin-1\u03b2 stimulation of osteoprotegerin in osteoblast-like cells","volume":"22","author":"Lambert","year":"2007","journal-title":"J. Bone Mineral. Res."},{"issue":"3","key":"10.1016\/j.cytogfr.2026.06.002_bib39","first-page":"426","article-title":"Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts","volume":"31","author":"Kubota","year":"2004","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.cytogfr.2026.06.002_bib40","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5603\/MRJ.a2022.0037","article-title":"Evaluation of the associations between GDF-15, OPG, and IL-15 levels in CRC: preliminary results","volume":"7","author":"Robotycka","year":"2022","journal-title":"Med. Res. J."},{"issue":"10","key":"10.1016\/j.cytogfr.2026.06.002_bib41","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1074\/jbc.M707000200","article-title":"NOTCH1 regulates osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblast lineage cells","volume":"283","author":"Bai","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.cytogfr.2026.06.002_bib42","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/03008207.2017.1290085","article-title":"Osteoblast\u2013osteoclast interactions","volume":"59","author":"Chen","year":"2018","journal-title":"Connect. Tissue Res."},{"issue":"11","key":"10.1016\/j.cytogfr.2026.06.002_bib43","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1096\/fba.2020-00058","article-title":"Current advances in regulation of bone homeostasis","volume":"2","author":"Al-Bari","year":"2020","journal-title":"Faseb Bioadv."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.06.002_bib44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00774-020-01162-6","article-title":"Osteoclast differentiation by RANKL and OPG signaling pathways","volume":"39","author":"Udagawa","year":"2021","journal-title":"J. Bone Mineral. Metab."},{"issue":"12","key":"10.1016\/j.cytogfr.2026.06.002_bib45","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1210\/en.2003-0717","article-title":"Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption","volume":"144","author":"Nakamura","year":"2003","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.cytogfr.2026.06.002_bib46","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/jcb.21129","article-title":"Osteoprotegerin expression in dendritic cells increases with maturation and is NF-\u03baB-dependent","volume":"100","author":"Schoppet","year":"2007","journal-title":"J. Cell. Biochem."},{"issue":"6","key":"10.1016\/j.cytogfr.2026.06.002_bib47","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1074-7613(03)00326-1","article-title":"Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin","volume":"19","author":"Ashcroft","year":"2003","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.cytogfr.2026.06.002_bib48","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.cytogfr.2013.06.001","article-title":"Osteoprotegerin: multiple partners for multiple functions","volume":"24","author":"Baud\u2019huin","year":"2013","journal-title":"Cytokine & Growth Factor. Rev."},{"issue":"8","key":"10.1016\/j.cytogfr.2026.06.002_bib49","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/ijc.21606","article-title":"Osteoprotegerin (OPG)\u2014a potential new role in the regulation of endothelialcell phenotype and tumour angiogenesis?","volume":"118","author":"Cross","year":"2006","journal-title":"Int. J. Cancer"},{"issue":"11","key":"10.1016\/j.cytogfr.2026.06.002_bib50","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/01.RES.0000149165.99974.12","article-title":"Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin","volume":"95","author":"Collin-Osdoby","year":"2004","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.cytogfr.2026.06.002_bib51","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.atherosclerosis.2008.09.033","article-title":"Osteoprotegerin, vascular calcification and atherosclerosis","volume":"204","author":"Van Campenhout","year":"2009","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.cytogfr.2026.06.002_bib52","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/cvr\/cvr084","article-title":"Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification","volume":"91","author":"Di Bartolo","year":"2011","journal-title":"Cardiovasc. Res."},{"issue":"9","key":"10.1016\/j.cytogfr.2026.06.002_bib53","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes. & Dev."},{"issue":"6b","key":"10.1016\/j.cytogfr.2026.06.002_bib54","first-page":"3809","article-title":"Osteoprotegerin is expressed in colon carcinoma cells","volume":"25","author":"Pettersen","year":"2005","journal-title":"Anticancer. Res."},{"key":"10.1016\/j.cytogfr.2026.06.002_bib55","article-title":"Tumor microenvironment shapes colorectal cancer progression, metastasis, and treatment responses","volume":"9","author":"Li","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.cytogfr.2026.06.002_bib56","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.3389\/fimmu.2021.742358","article-title":"TNFRSF11B suppresses memory CD4+ T cell infiltration in the colon cancer microenvironment: a multiomics integrative analysis","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.06.002_bib57","doi-asserted-by":"crossref","first-page":"22217","DOI":"10.1038\/s41598-023-49312-w","article-title":"Downregulation of osteoprotegerin in colorectal cancer cells promotes liver metastasis via activating tumor-associated macrophage","volume":"13","author":"Hirata","year":"2023","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.cytogfr.2026.06.002_bib58","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41419-024-06806-3","article-title":"RANKL\/RANK signaling recruits Tregs via the CCL20-CCR6 pathway and promotes stemness and metastasis in colorectal cancer","volume":"15","author":"Ouyang","year":"2024","journal-title":"Cell. Death Dis."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.06.002_bib59","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/s41467-021-22450-3","article-title":"Interleukin-11-expressing fibroblasts have a unique gene signature correlated with poor prognosis of colorectal cancer","volume":"12","author":"Nishina","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.06.002_bib60","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10456-008-9127-z","article-title":"Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function","volume":"12","author":"Mcgonigle","year":"2009","journal-title":"Angiogenesis"},{"issue":"11","key":"10.1016\/j.cytogfr.2026.06.002_bib61","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1007\/s10620-013-2851-2","article-title":"Osteoprotegerin exerts its pro-inflammatory effects through nuclear factor-\u03baB activation","volume":"58","author":"Nahidi","year":"2013","journal-title":"Dig. Dis. Sci."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.06.002_bib62","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41467-019-13883-y","article-title":"Osteoprotegerin-dependent M cell self-regulation balances gut infection and immunity","volume":"11","author":"Kimura","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.06.002_bib63","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41392-025-02148-4","article-title":"Invasion and metastasis in cancer: molecular insights and therapeutic targets","volume":"10","author":"Li","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"9","key":"10.1016\/j.cytogfr.2026.06.002_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093391","article-title":"Colorectal cancer invasion and atrophy of the enteric nervous system: potential feedback and impact on cancer progression","volume":"21","author":"Godlewski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.cytogfr.2026.06.002_bib65","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1158\/1078-0432.CCR-10-2884","article-title":"Clinical significance of osteoprotegerin expression in human colorectal cancer","volume":"17","author":"Tsukamoto","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.cytogfr.2026.06.002_bib66","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41419-021-03642-7","article-title":"RANK promotes colorectal cancer migration and invasion by activating the Ca2+-calcineurin\/NFATC1-ACP5 axis","volume":"12","author":"Liang","year":"2021","journal-title":"Cell. Death Dis."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.06.002_bib67","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0039-6109(05)70543-0","article-title":"Angiogenesis in colorectal cancer","volume":"77","author":"Saclarides","year":"1997","journal-title":"Surg. Clin. North. Am."},{"issue":"9","key":"10.1016\/j.cytogfr.2026.06.002_bib68","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.06.002_bib69","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12943-025-02465-w","article-title":"Circulating tumor cells: mechanisms and clinical significance in colorectal cancer metastasis","volume":"24","author":"Ren","year":"2025","journal-title":"Mol. Cancer"},{"issue":"48","key":"10.1016\/j.cytogfr.2026.06.002_bib70","doi-asserted-by":"crossref","first-page":"79319","DOI":"10.18632\/oncotarget.12686","article-title":"Downregulation of osteoprotegerin expression in metastatic colorectal carcinoma predicts recurrent metastasis and poor prognosis","volume":"7","author":"Moon","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.cytogfr.2026.06.002_bib71","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.mehy.2018.06.013","article-title":"Bone resorption and bone metastasis risk","volume":"118","author":"Mathis","year":"2018","journal-title":"Med. Hypotheses"},{"issue":"12","key":"10.1016\/j.cytogfr.2026.06.002_bib72","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/jbmr.3618","article-title":"Understanding the bone in cancer metastasis","volume":"33","author":"Fornetti","year":"2018","journal-title":"J. Bone Mineral. Res."},{"issue":"9","key":"10.1016\/j.cytogfr.2026.06.002_bib73","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.cell.2021.03.011","article-title":"The bone microenvironment invigorates metastatic seeds for further dissemination","volume":"184","author":"Zhang","year":"2021","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.06.002_bib74","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.canlet.2009.01.011","article-title":"Mechanism of bone metastasis: the role of osteoprotegerin and of the host-tissue microenvironment-related survival factors","volume":"283","author":"Fili","year":"2009","journal-title":"Cancer Lett."},{"issue":"6294","key":"10.1016\/j.cytogfr.2026.06.002_bib75","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aaf2403","article-title":"Visualization and analysis of gene expression in tissue sections by spatial transcriptomics","volume":"353","author":"St\u00e5hl","year":"2016","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.cytogfr.2026.06.002_bib76","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41419-024-06598-6","article-title":"Integrating spatial and single-cell transcriptomics reveals tumor heterogeneity and intercellular networks in colorectal cancer","volume":"15","author":"Xiao","year":"2024","journal-title":"Cell. death & Dis."},{"issue":"7","key":"10.1016\/j.cytogfr.2026.06.002_bib77","first-page":"2306","article-title":"Serum osteoprotegerin levels in healthy controls and cancer patients","volume":"8","author":"Lipton","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.cytogfr.2026.06.002_bib78","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1159\/000487101","article-title":"Correlation between baseline osteoprotegerin serum levels and prognosis of advanced-stage colorectal cancer patients","volume":"45","author":"De Toni","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.cytogfr.2026.06.002_bib79","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.euros.2024.03.008","article-title":"Interassay variability and clinical implications of five different prostate-specific antigen assays","volume":"63","author":"Kaufmann","year":"2024","journal-title":"Eur. Urol. Open. Sci."},{"issue":"4","key":"10.1016\/j.cytogfr.2026.06.002_bib80","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.tranon.2018.05.012","article-title":"Plasma protein profiling reveal osteoprotegerin as a marker of prognostic impact for colorectal cancer","volume":"11","author":"Birgisson","year":"2018","journal-title":"Transl. Oncol."},{"issue":"3","key":"10.1016\/j.cytogfr.2026.06.002_bib81","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3892\/ol.2022.13216","article-title":"Capecitabine inhibits epithelial-to-mesenchymal transition and proliferation of colorectal cancer cells by mediating the RANK\/RANKL pathway","volume":"23","author":"Shao","year":"2022","journal-title":"Oncol. Lett."},{"issue":"3","key":"10.1016\/j.cytogfr.2026.06.002_bib82","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/jbmr.244","article-title":"Anticancer efficacy of Apo2L\/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo","volume":"26","author":"Zinonos","year":"2011","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.06.002_bib83","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1757-2215-5-34","article-title":"Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis","volume":"5","author":"Lane","year":"2012","journal-title":"J. Ovarian Res."},{"issue":"3","key":"10.1016\/j.cytogfr.2026.06.002_bib84","doi-asserted-by":"crossref","first-page":"210","DOI":"10.4161\/mabs.1.3.8592","article-title":"Denosumab","volume":"1","author":"Pageau","year":"2009","journal-title":"mAbs"},{"issue":"10","key":"10.1016\/j.cytogfr.2026.06.002_bib85","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00402-019-03167-x","article-title":"Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature","volume":"139","author":"Luengo-Alonso","year":"2019","journal-title":"Arch. Orthop. Trauma. Surg."},{"issue":"9810","key":"10.1016\/j.cytogfr.2026.06.002_bib86","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.cytogfr.2026.06.002_bib87","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized Phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.cytogfr.2026.06.002_bib88","first-page":"679","article-title":"Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors","volume":"22","author":"Henry","year":"2014","journal-title":"Support. Care Cancer"},{"issue":"9","key":"10.1016\/j.cytogfr.2026.06.002_bib89","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.cytogfr.2026.06.002_bib90","first-page":"141","article-title":"Drug resistance and combating drug resistance in cancer","volume":"2","author":"Wang","year":"2019","journal-title":"Cancer Drug. Resist."},{"issue":"6","key":"10.1016\/j.cytogfr.2026.06.002_bib91","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1431088","article-title":"RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer","volume":"7","author":"Ahern","year":"2018","journal-title":"OncoImmunology"},{"issue":"4","key":"10.1016\/j.cytogfr.2026.06.002_bib92","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1158\/2326-6066.CIR-23-0184","article-title":"Immune modulation with RANKL blockade through Denosumab treatment in patients with cancer","volume":"12","author":"Chang","year":"2024","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.cytogfr.2026.06.002_bib93","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/gt.2010.5","article-title":"TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer","volume":"17","author":"Ziauddin","year":"2010","journal-title":"Gene Ther."},{"issue":"7","key":"10.1016\/j.cytogfr.2026.06.002_bib94","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1093\/annonc\/mdt057","article-title":"A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer","volume":"24","author":"Cohn","year":"2013","journal-title":"Ann. Oncol."},{"issue":"18","key":"10.1016\/j.cytogfr.2026.06.002_bib95","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/jnci\/djt225","article-title":"Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment","volume":"105","author":"Hu","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.06.002_bib96","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","article-title":"Drug repurposing for cancer therapy","volume":"9","author":"Xia","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"12","key":"10.1016\/j.cytogfr.2026.06.002_bib97","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1038\/s41590-023-01678-9","article-title":"Decoding the tumor microenvironment with spatial technologies","volume":"24","author":"Walsh","year":"2023","journal-title":"Nat. Immunol."},{"issue":"15","key":"10.1016\/j.cytogfr.2026.06.002_bib98","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.3390\/cancers15153835","article-title":"Transcriptomic maps of colorectal liver metastasis: machine learning of gene activation patterns and epigenetic trajectories in support of precision medicine","volume":"15","author":"Ashekyan","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.cytogfr.2026.06.002_bib99","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jare.2024.06.018","article-title":"Osteoprotegerin mediates adipogenesis in obesity","volume":"62","author":"Lyu","year":"2024","journal-title":"J. Adv. Res."},{"issue":"3","key":"10.1016\/j.cytogfr.2026.06.002_bib100","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10549-021-06400-7","article-title":"Physical activity and Mediterranean diet as potential modulators of osteoprotegerin and soluble RANKL in gBRCA1\/2 mutation carriers: results of the lifestyle intervention pilot study LIBRE-1","volume":"190","author":"Neirich","year":"2021","journal-title":"Breast Cancer Res. Treat."}],"container-title":["Cytokine & Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610126000432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610126000432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:12:46Z","timestamp":1783635166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610126000432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":100,"alternative-id":["S1359610126000432"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2026.06.002","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of osteoprotegerin in colorectal cancer: Molecular interactions, mechanistic insights, and therapeutic implications","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2026.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}